ONCOC4: CESALATAMIG MONOTHERAPY ACHIEVES 33% OBJECTIVE RESPONSE RATE, 90% DISEASE CONTROL RATE AT 10 MG/KG IN PD-(L)1-RESISTANT NSCLC

Reuters · 2d ago

Please log in to view news